Lung cancer: recognition, NLCSP screening and the GP's role in AU practice

Lung cancer kills more Australians each year than any other cancer — approximately 8,800 deaths annually, ahead of colorectal, breast, and prostate cancer combined. The core reason survival is so poor (overall five-year survival ~22%) is late diagnosis: by the time most cases are detected, the cancer has spread beyond the scope of curative surgery. The single most impactful thing Australian general practice can do is recognise the disease earlier, connect eligible patients with the new national screening program, and stop every smoker at every GP visit.

From 1 July 2025, Australia has a National Lung Cancer Screening Program (NLCSP) — a biennial low-dose CT program for eligible high-risk individuals. This represents a genuine opportunity for stage shift.

A. Core clinical — the AU general-practice framework

Understanding the disease

Lung cancer arises from the bronchial epithelium or pulmonary parenchyma. The main categories are:

Non-small-cell lung cancer (NSCLC) — approximately 85%:

• Adenocarcinoma — now the most common subtype; increasingly occurs in never-smokers and women; arises in lung periphery
• Squamous cell carcinoma — central, airway-related, strongly smoking-linked
• Large cell carcinoma — less common; often aggressive

Small-cell lung cancer (SCLC) — approximately 15%:

• Almost exclusively smoking-related; highly sensitive to chemotherapy initially but prone to early relapse
• Frequently presents with paraneoplastic syndromes

Carcinoid tumours — well-differentiated neuroendocrine tumours; relatively indolent; often surgically curable.

Molecular profiling of NSCLC biopsy tissue is now mandatory at diagnosis. Identifying targetable driver mutations (EGFR, ALK, ROS1, KRAS G12C, BRAF V600E, RET, HER2, MET exon 14, NTRK) and PD-L1 expression opens PBS-funded targeted therapy pathways via eviQ protocols. Without profiling, people miss treatments that can significantly extend survival with better quality of life than chemotherapy alone.

Epidemiology

• ~14,300 new cases and ~8,800 deaths per year — leading cancer killer per AIHW 2024
• 5-year relative survival ~22% overall; ~70% at stage I; ~3% at stage IV — explaining why stage shift is the paramount goal
• Aboriginal and Torres Strait Islander Australians have approximately twice the incidence of lung cancer and worse stage-adjusted outcomes
• Adenocarcinoma is now the most common subtype overall, including in never-smokers and women, partly due to changing smoking patterns and improved detection of peripheral lesions

Risk factors

Tobacco smoking — the cause of approximately 85% of lung cancer in Australia. Risk rises with pack-years (number of packs per day × years of smoking) and with age at which smoking began. Risk remains elevated for decades after quitting but is progressively lower the longer ago the person quit.

Other established risk factors include: asbestos and other occupational carcinogens (silica, diesel exhaust, chromium, arsenic — see occupational lung disease); residential radon; underlying COPD; idiopathic pulmonary fibrosis; prior thoracic radiotherapy; and HIV infection.

Family history of lung cancer confers a modest independent risk beyond shared smoking history.

The National Lung Cancer Screening Program (NLCSP)

The NLCSP launched on 1 July 2025 — Australia’s first national lung cancer screening program — based on evidence from the NLST (20% relative reduction in lung-cancer mortality, published NEJM 2011) and NELSON (24% reduction in men, 33% in women, published NEJM 2020) trials.

Eligibility criteria per Cancer Australia:

• Age 50–70 years
• Smoking history of ≥30 pack-years (e.g. 1 pack per day × 30 years, or 2 packs per day × 15 years)
• Currently smoking or quit within the past 10 years
• No current symptoms suggestive of lung cancer (symptomatic patients require the urgent 2-week diagnostic pathway)

The test: biennial low-dose chest CT (LDCT) at an accredited radiology site. Results are reported using a Lung-RADS protocol, with follow-up imaging or referral based on nodule size and characteristics.

The GP’s role in the NLCSP:

• Identify eligible patients using tobacco status data and pack-year calculation
• Refer eligible patients to participating sites
• Follow up Lung-RADS results and coordinate any downstream investigation
• Integrate screening visits with smoking cessation at every contact

A critical safety note for smokers: beta-carotene and high-dose vitamin A supplements are contraindicated in smokers based on the CARET trial and ATBC trial — both found increased, not decreased, lung-cancer mortality in smokers given these supplements. Counsel patients explicitly.

Recognising lung cancer in general practice

Symptoms are often non-specific and overlap with common respiratory conditions. Features that should trigger timely investigation in a current or former smoker:

• Cough lasting more than three weeks — new, changed character, or unresponsive to usual treatment
• Haemoptysis — any amount of blood in sputum in an adult; the most important red flag
• Unexplained chest pain — particularly shoulder pain (Pancoast superior sulcus tumour)
• Dyspnoea out of proportion to known lung disease
• Unintentional weight loss
• Hoarse voice — recurrent laryngeal nerve involvement
• Recurrent or slow-resolving chest infections

Paraneoplastic features that can precede the chest diagnosis:

• SIADH (hyponatraemia) — SCLC
• Hypercalcaemia — squamous cell carcinoma (PTHrP production)
• Lambert-Eaton myasthenic syndrome — proximal muscle weakness that transiently improves with repetition (SCLC)
• Clubbing and hypertrophic pulmonary osteoarthropathy
• Horner’s syndrome (miosis, ptosis, anhidrosis) — Pancoast tumour invading the stellate ganglion

Investigations

In general practice (first-line):

• Chest X-ray (PA + lateral) — within two weeks for any current or former smoker with the above symptoms. A normal CXR does not exclude lung cancer — 20–25% are missed. Persistent symptoms warrant CT regardless.
• Full blood count, electrolytes, liver function, calcium, LDH — baseline and to screen for paraneoplastic syndromes
• Spirometry if dyspnoea is a feature

Specialist-coordinated investigations:

• CT chest + upper abdomen — the definitive initial imaging; ordered urgently when symptoms persist or CXR is abnormal
• Tissue diagnosis — bronchoscopy with EBUS-TBNA (endobronchial ultrasound-guided transbronchial needle aspiration), CT-guided percutaneous biopsy, or surgical thoracoscopy
• Molecular profiling panel — EGFR, ALK, ROS1, KRAS G12C, BRAF, RET, HER2, MET exon 14, NTRK, and PD-L1 IHC — organised through specialist pathology under MSAC-approved pathways
• PET-CT for staging (Authority Required, specialist-initiated)
• MRI brain — all stage II or above NSCLC and all SCLC

A normal CXR in the context of persistent high-risk symptoms must lead to CT, not reassurance. Do not delay by prescribing empirical antibiotics and reviewing in six weeks.

B. Treatment — the GP-relevant framework

Treatment is led by a thoracic oncology multidisciplinary team (MDT). The Cancer Australia optimal care pathway and eviQ protocols govern treatment.

NSCLC stage I–II: lobectomy (or stereotactic body radiotherapy if inoperable) with adjuvant osimertinib for three years in EGFR-mutated resected disease (ADAURA trial).

NSCLC stage III: concurrent chemoradiation followed by 12 months of consolidation durvalumab (PBS Authority Required) per the PACIFIC trial — 5-year overall survival 42.9% versus 33.4%.

NSCLC stage IV — driver-mutation guided (PBS-funded):

• EGFR+ → osimertinib ± chemotherapy (FLAURA, FLAURA2)
• ALK+ → alectinib or lorlatinib (CROWN trial)
• KRAS G12C → sotorasib or adagrasib (CodeBreaK 100)
• No targetable driver, PD-L1 ≥50% → pembrolizumab monotherapy (KEYNOTE-024)
• No targetable driver, PD-L1 <50% → pembrolizumab + chemotherapy (KEYNOTE-189)

SCLC: platinum-etoposide chemotherapy combined with atezolizumab (IMpower133) or durvalumab (CASPIAN) is standard first-line for extensive-stage disease; thoracic radiotherapy and prophylactic cranial irradiation for limited-stage disease.

Smoking cessation must occur at every consultation — varenicline (Champix, PBS Authority Streamlined), nicotine replacement therapy, and bupropion (Zyban) are all PBS-accessible. Smoking cessation even after diagnosis improves treatment tolerability, response, and survival.

C. Survivorship shared care

After curative-intent treatment, GP shared care involves:

• CT chest every six months for two years, then annually for three further years; annual surveillance thereafter
• Monitoring for immunotherapy-related adverse effects — thyroiditis (monitor TSH), colitis, hepatitis, pneumonitis, rare myocarditis
• Cardiotoxicity surveillance after thoracic radiotherapy
• Mental health — depression screening, distress thermometer ≥4 triggers Mental Health Treatment Plan
• Pulmonary rehabilitation and exercise physiology referral
• Nutrition — dietitian referral; cachexia management
• Written survivorship plan, updated annually; involve Aboriginal Liaison Officer for ATSI patients

D. Australian operations

MBS items

Chest X-ray items 58500/58503; CT chest items 56407/56412 (Authority for indication in many contexts); PET-CT item 61628 (Authority Required, specialist-initiated); bronchoscopy items 38415/38418; MRI brain item 63551; GP consultations items 23/36/44. GPCCMP items 965/967 for chronic disease management; Mental Health Treatment Plan items 2715/2717; ATSI health assessment item 715. NLCSP MBS items active from 1 July 2025 under MSAC 1699.

Palliative care MBS items 3005–3093 for end-of-life management. Case conferencing items 132/133 for complex MDT coordination.

PBS-funded targeted and immunotherapy

All targetable driver therapies (osimertinib, alectinib, lorlatinib, crizotinib, entrectinib, sotorasib, adagrasib, selpercatinib, dabrafenib + trametinib, trastuzumab deruxtecan) are PBS Authority Required, Section 100 HSD, specialist-prescribed. Immunotherapy (pembrolizumab, atezolizumab, nivolumab, durvalumab) similarly Authority Required. Smoking cessation: varenicline Authority Streamlined; bupropion Authority; NRT PBS-subsidised for Aboriginal and Torres Strait Islander Australians.

Consumer resources

• Lung Foundation Australia — information, peer support, financial counselling
• Cancer Council Australia — 13 11 20 — information and support line
• Cancer Australia — NLCSP information
• HealthDirect

E. Special populations

Aboriginal and Torres Strait Islander Australians. Incidence is approximately twice the general population and stage at diagnosis is later. The NLCSP has a specific equity-of-access mandate per Cancer Australia. ATSI Health Assessment (MBS item 715) is an opportunity to screen for eligibility and address smoking cessation within a culturally safe framework. Engage Aboriginal Liaison Officers early in diagnosis and during treatment.

Never-smokers. Approximately 15% of lung cancers occur in people who have never smoked. EGFR mutations and ALK rearrangements are more common in this group. Never-smokers with persistent respiratory symptoms should be investigated on the same basis as smokers — the absence of smoking history does not exclude lung cancer.

Occupational exposure. People with significant asbestos, silica, or diesel exhaust exposure may have occupational grounds for workers’ compensation claims, depending on state legislation and documentation of the workplace exposure. Document occupational history in any suspected or confirmed lung cancer case.

People with COPD. COPD and lung cancer share tobacco as a primary cause and frequently co-exist. Persistent symptoms in a person with known COPD should not be attributed solely to the COPD without considering whether an underlying malignancy is contributing. Annual review in COPD should include an opportunistic lung cancer symptom screen and NLCSP eligibility check.

When to escalate

Send to emergency department immediately for:

• Superior vena cava (SVC) obstruction — facial plethora, distended neck veins, dyspnoea worsening on lying flat
• Suspected spinal cord compression — new back pain with bilateral leg weakness, numbness, or bowel or bladder change
• Massive haemoptysis (more than 200 mL of blood)
• Hypercalcaemic crisis — confusion, severe constipation, polyuria with confirmed high calcium
• Neutropenic fever in a patient on chemotherapy
• Suspected immune-related adverse event — myocarditis, pneumonitis, or colitis in anyone on immunotherapy

Urgent 2-week GP referral (same-week if possible) for:

• Any haemoptysis in an adult, regardless of volume
• Persistent cough plus smoking history, especially if cough has changed character
• Suspicious or indeterminate finding on any chest imaging
• Unexplained weight loss with respiratory symptoms in a current or former smoker
• Signs of SVC obstruction or Pancoast syndrome on examination

Routine referral for: incidental sub-centimetre pulmonary nodule — manage per Fleischner Society guidelines.

What this article is and is not

This article draws on current Australian guidelines — Cancer Australia, AIHW, RACGP, Therapeutic Guidelines (eTG), eviQ, Lung Foundation Australia, and key clinical trials — to provide general health information about lung cancer in the context of Australian general practice. It is not personal medical advice and does not create a doctor–patient relationship.

All decisions about investigation, referral urgency, and treatment are made with your GP, respiratory specialist, and oncology team based on your individual circumstances.

For consumer-friendly information: Lung Foundation Australia, Cancer Council 13 11 20, HealthDirect. For NLCSP eligibility: Cancer Australia.

---

Sources cited

1. AIHW — Cancer Data in Australia 2024
2. Cancer Australia — NLCSP (1 July 2025)
3. Cancer Australia — Optimal care pathway for lung cancer
4. RACGP — Suspected cancer and 2-week pathway
5. Therapeutic Guidelines (eTG) — Lung cancer
6. eviQ — Lung cancer treatment protocols
7. PBS — Lung cancer targeted and immunotherapy listings
8. NLST — Aberle DR et al. NEJM 2011;365:395
9. NELSON — de Koning HJ et al. NEJM 2020;382:503
10. CARET — Omenn GS et al. NEJM 1996;334:1150
11. Lung Foundation Australia
12. Cancer Council Australia — Lung cancer